OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib | HMA-EMA Catalogues of real-world data sources and studies

Study protocol

Initial protocol

OPTIMIS_PRO

English (1.86 MB - PDF) View document

Updated protocol

OPTIMIS_PRO_v3_2015-09-04 FINAL

First published: 22/02/2024

English (2.17 MB - PDF) View document

Study results

16560_EU PAS_Abstract_2018-10-10

English (227.73 KB - PDF) View document

Study report

16560 OPTIMIS_Report Addendum_v1.0_20181015_Redacted

English (1.1 MB - PDF) View document

16560 OPTIMIS_Report_v1.0_20180529_Redacted

English (2.77 MB - PDF) View document

Other information

Study, other information

16560 OPTIMIS_Report_v1.0_20180529_Redacted.pdf

English (2.77 MB - PDF) View document

OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib